<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04268784</url>
  </required_header>
  <id_info>
    <org_study_id>DNLI-F-0001</org_study_id>
    <secondary_id>2019-004027-21</secondary_id>
    <nct_id>NCT04268784</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Single-Center, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Denali Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Denali Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study carried out at a single site in 88 healthy male subjects and healthy
      female subjects of non childbearing potential to investigate the safety, tolerability,
      pharmacokinetics (PK) and pharmacodynamics (PD) of DNL343.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events (TEAEs) including serious adverse events (SAEs), and discontinuations due to TEAEs</measure>
    <time_frame>Up to 20 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter: The area under the concentration-time curve from time zero extrapolated to infinity (AUC0-∞) of DNL343 in plasma</measure>
    <time_frame>Up to 20 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter: The area under the concentration-time curve from zero to 12 or 24 hours for twice daily (BID) or once daily (QD) dosing, respectively (AUC0-τ) of DNL343 in plasma</measure>
    <time_frame>Up to 20 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter: Maximum observed concentration (Cmax) of DNL343 in plasma</measure>
    <time_frame>Up to 20 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter: Area under the concentration-time curve from time zero to the time of last quantifiable concentration (AUC[0-last]) of DNL343 in plasma</measure>
    <time_frame>Up to 20 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter: Time to maximum observed concentration (Tmax) of DNL343 in plasma</measure>
    <time_frame>Up to 20 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter: Apparent terminal elimination rate constant (λz) with the respective t½ of DNL343 in plasma</measure>
    <time_frame>Up to 20 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameter: The amount of DNL343 excreted in urine from time zero to 48 hours postdose (Ae48)</measure>
    <time_frame>Up to 20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Estimation of renal clearance (CLR)</measure>
    <time_frame>Up to 20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Concentration of DNL343 in cerebrospinal fluid (CSF)</measure>
    <time_frame>Up to 20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The PD of DNL343 in blood as measured by percent reduction of integrated stress response (ISR) protein levels measured by enzyme-linked immunosorbent assay (ELISA)</measure>
    <time_frame>Up to 20 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The PD of DNL343 in blood as measured by percent reduction in ISR gene expression levels measured by quantitative polymerase chain reaction (qPCR)</measure>
    <time_frame>Up to 20 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>DNL343</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A: Single-ascending dose; Cohort B: Multiple-ascending doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort A: Single-ascending dose; Cohort B: Multiple-ascending doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DNL343</intervention_name>
    <description>Single and repeating oral dose(s)</description>
    <arm_group_label>DNL343</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single and repeating oral dose(s)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Women of non-childbearing potential and men; aged 18-50 years, inclusive

          -  BMI 18-32 kg/m², inclusive, and body weight of at least 50 kg

        Key Exclusion Criteria:

          -  History of clinically significant neurologic, psychiatric, endocrine, pulmonary,
             cardiovascular, gastrointestinal, hepatic, pancreatic, renal, metabolic, hematologic,
             immunologic, or allergic disease, or other major disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Tsai, MD</last_name>
    <role>Study Director</role>
    <affiliation>Denali Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Human Drug Research (CHDR)</name>
      <address>
        <city>Leiden</city>
        <state>South Holland</state>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Project Manager</last_name>
      <phone>+31 71 5246 400</phone>
      <email>maurits.vissers@chdr.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

